RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis - Trial NCT06216938
Access comprehensive clinical trial information for NCT06216938 through Pure Global AI's free database. This Phase 1 trial is sponsored by Yana Najjar and is currently Recruiting. The study focuses on Melanoma. Target enrollment is 25 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Yana Najjar
University of Pittsburgh
Timeline & Enrollment
Phase 1
Feb 02, 2024
Jul 31, 2028
Primary Outcome
Rate of Sentinel Lymph Node (SLN) Positivity
Summary
This early-phase study will examine Vusolimogene Oderparepvec, a genetically modified
 oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic,
 immunostimulating and antineoplastic activities. Upon administration, vusolimogene
 oderparepvec specifically targets, infects and replicates in tumor cells and does not infect
 healthy cells. This results in tumor cell lysis and the release of virus particles which
 infect and replicate within nearby tumor cells, resulting in tumor cel death. The immune
 system is activated by the released tumor-associated antigens (TAAs) from the tumor cells
 creating an anti-tumor immune response against the tumor cells, thereby further killing the
 tumor cells. The virus itself also elicits a tumor-specific systemic immune and cytotoxic
 T-lymphocyte (CTL) response, thereby killing nearby non-infected tumor cells.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06216938
Non-Device Trial